MARKET

TPST

TPST

Tempest Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.55
-0.56
-3.71%
After Hours: 14.32 -0.23 -1.58% 16:38 09/24 EDT
OPEN
15.28
PREV CLOSE
15.11
HIGH
15.44
LOW
14.42
VOLUME
9.81K
TURNOVER
--
52 WEEK HIGH
41.55
52 WEEK LOW
10.39
MARKET CAP
97.53M
P/E (TTM)
-0.5823
1D
5D
1M
3M
1Y
5Y
BRIEF-Tempest Announces First Patient Dosed In Randomized Study Evaluating TPST-1120
reuters.com · 5d ago
Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche
Trial to Evaluate TPST-1120/atezolizumab/bevacizumab triplet compared to atezolizumab/bevacizumab aloneSOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing p...
GlobeNewswire · 5d ago
Tempest Doses First Patient in Phase 1b/2 Trial of TPST-1120 to Treat Hepatocellular Carcinoma
MT Newswires · 5d ago
Tempest Enters Into Exclusive License Agreement With The University Of California For Novel Cancer Target
Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that it has
Benzinga · 09/13 12:07
Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target
• Russell Vance, PhD joins Tempest Advisory Board SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine b...
GlobeNewswire · 09/13 12:00
Tempest to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today...
GlobeNewswire · 09/09 20:01
Foresite Capital Management IV, LLC Buys Lyell Immunopharma Inc, Quantum-Si Inc, Nurix ...
GuruFocus News · 08/17 19:38
Tempest Therapeutics Q2 EPS $(7.63) Up From $(11.42) YoY
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(7.63) per share. This is a 33.19 percent increase over losses of $(11.42) per share from the same period last year.
Benzinga · 08/12 20:36
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TPST. Analyze the recent business situations of Tempest Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TPST stock price target is 2.000 with a high estimate of 2.000 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 71
Institutional Holdings: 2.11M
% Owned: 31.40%
Shares Outstanding: 6.70M
TypeInstitutionsShares
Increased
8
124.11K
New
8
1.39M
Decreased
7
49.95K
Sold Out
17
96.45K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Director
Mike Raab
President/Director
Tom Dubensky
Chief Executive Officer/Director
Stephen Brady
Chief Financial Officer/Chief Accounting Officer
Jennifer Minai-azary
Other
Thomas Hoover
Other
Samuel Whiting
Director
Christine Pellizzari
Director
Ronit Simantov
Director
Tom Woiwode
Director
Stella Xu
Independent Director
Geoffrey Nichol
No Data
About TPST
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.

Webull offers kinds of Tempest Therapeutics Inc stock information, including NASDAQ:TPST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TPST stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TPST stock methods without spending real money on the virtual paper trading platform.